Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

The small molecule compound Y15 and PF04554878 in TT cells

ABSTRACT: Global gene expression in TT cells treated with FAK inhibitors

ORGANISM(S): Homo sapiens

PROVIDER: GSE55619 | GEO | 2015/07/03

SECONDARY ACCESSION(S): PRJNA240222

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

The small molecule compound Y15 and PF04554878 in TT cells

Project description:Global gene expression in TT cells treated with FAK inhibitors TT cells were untreated and treated with Y15 small molecule FAK inhibitor at 10 microM or another FAK inhibitor PF04554878 at 10microM, total RNA was isolated and gene expression was analyzed using Illumina chips

2015-07-03 | E-GEOD-55619 | biostudies-arrayexpress

Targeting FAK and EGFR/HER-2 with small molecule inhibitors in SKBR-3 breast cancer cell

Project description:Targeting FAK with two different FAK inhibitors and Lapatinib demonstrated different signaling mechanisms

2015-09-25 | GSE61756 | GEO

The small molecule compound P2 in HCT116p53-/- and HCT116p53+/+ cells

Project description:Global gene expression in HCT116p53-/- and HCT116p53+/+ cells HCT116p53-/- and p53+/+ were untreated and treated with P2 small molecule compound at 25 microM, total RNA was isolated and gene expression was analyzed using Illumina chips

2012-11-23 | E-GEOD-33918 | biostudies-arrayexpress

Project description:tt

| PRJEB51254 | ENA

The small molecule compound P2 in HCT116p53-/- and HCT116p53+/+ cells

Project description:Global gene expression in HCT116p53-/- and HCT116p53+/+ cells

2012-11-23 | GSE33918 | GEO

TT-Seq captures the human transient transcriptome

Project description:A large portion of the genome is transcribed but many of the resulting RNAs live only transiently and can generally not be mapped. Here we develop transient transcriptome sequencing (TT-Seq), a protocol that maps transcriptionally active regions in a nearly uniform manner and allows for unbiased monitoring of cellular RNA synthesis activity. Application of TT-Seq to human K562 cells recovers stable mRNAs and long intergenic non-coding RNAs, and additionally maps over 10,000 transient RNAs including enhancer RNAs, antisense RNAs, promoter-associated upstream antisense and convergent RNAs. TT-Seq also provides RNA half-lives, and reveals that transient RNAs are short and lack U1 motifs and secondary structure. TT-Seq further uncovers transcription termination sites and reveals a universal DNA motif for RNA polymerase II release.

2016-06-03 | GSE75792 | GEO

ERK5 suppression overcomes FAK inhibitor resistance in mutant KRAS-driven non-small cell lung cancer [p826_PND_A549]

Project description:Mutated KRAS serves as the oncogenic driver in 30% of non-small cell lung cancers (NSCLCs) and is associated with metastatic and therapy-resistant tumors. Focal Adhesion Kinase (FAK) acts as a mediator in sustaining KRAS-driven lung tumors, and although FAK inhibitors are currently undergoing clinical development, clinical data indicated that their efficacy in producing long-term anti-tumor responses is limited. Here we revealed two FAK interactors, extracellular-signal-regulated kinase 5 (ERK5) and cyclin-dependent kinase 5 (CDK5) as key players underlying FAK-mediated maintenance of KRAS mutant NSCLC. Inhibition of ERK5 and CDK5 synergistically suppressed FAK function, decreased proliferation and induced apoptosis owing to exacerbated ROS-induced DNA damage. Accordingly, concomitant pharmacological inhibition of ERK5 and CDK5 in a mouse model of KrasG12D-driven lung adenocarcinoma suppressed tumor progression and promoted cancer cell death. Cancer cells resistant to FAK inhibitors showed enhanced ERK5-FAK signaling dampening DNA damage. Notably, ERK5 inhibition prevents resistance to FAK inhibitors, significantly enhancing the efficacy of antitumor responses. Therefore, we propose ERK5 inhibition as a potential co-targeting strategy to counteract FAK inhibitor resistance in NSCLC.

2024-09-16 | GSE255643 | GEO

ERK5 suppression overcomes FAK inhibitor resistance in mutant KRAS-driven non-small cell lung cancer [p697_ERK5]

2024-09-16 | GSE255628 | GEO

TT-seq on COMPASS-degron cells

Project description:TT-seq on COMPASS-degron cells

| PRJNA753083 | ENA

TT-seq on INTS11-degron cells

Project description:TT-seq on INTS11-degron cells

| PRJNA957695 | ENA